Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than comprehensive financial performance.
Material Changes
There are no material changes to financial performance reported in this document. The only reported change is an increase in the interest of Mr. D J Phelan in Ordinary share ADRs.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or general management commentary. It details a specific transaction where Mr. D J Phelan increased his holdings following the re-investment of a dividend paid to shareholders on January 8, 2009. The transaction occurred at a price of $39.00 per ADR, resulting in a total interest of 208.24 ADRs.
Investor Verification Checklist
- Verify the total number of ADRs held by Mr. D J Phelan post-transaction (208.24).
- Confirm the dividend re-investment price of $39.00 per ADR.
- Check the date of the dividend payment (January 8, 2009) and the notification date (January 13, 2009).
- Note that this filing does not contain quarterly or annual financial results.